Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Exelixis Inc EXEL

Healthcare Biotechnology
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved... see more

Recent & Breaking News (NDAQ:EXEL)

11 Stocks That Moved From ESMO 2018

Benzinga.com  October 22, 2018

Exelixis Announces Results from the Dose-Escalation Stage of the Phase 1b COSMIC-021 Study of Cabozantinib in Combination with Atezolizumab in Previously Untreated Advanced Renal Cell Carcinoma

Business Wire October 22, 2018

Exelixis Announces Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib in Patients with Advanced Renal Cell Carcinoma

Business Wire October 20, 2018

Exelixis to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018

Business Wire October 18, 2018

Report: Exploring Fundamental Drivers Behind Bellicum Pharmaceuticals, Social Reality, Exelixis, Edgewell Personal Care, Cronos Group, and Acacia Communications — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire October 17, 2018

Cabozantinib to Be Featured in 13 Presentations at ESMO 2018 Congress

Business Wire October 8, 2018

Exelixis Initiates Phase 3 Pivotal Trial (COSMIC-311) of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy

Business Wire October 8, 2018

Exelixis to Present at the Cantor Fitzgerald Global Healthcare Conference on October 2, 2018

Business Wire September 25, 2018

The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding

Benzinga.com  September 21, 2018

Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma

Business Wire September 21, 2018

Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma

Business Wire September 19, 2018

The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares

Benzinga.com  September 18, 2018

Exelixis Announces New Recommendations for CABOMETYX® (Cabozantinib) Tablets in Updated National Comprehensive Cancer Network Clinical Practice Guidelines

Business Wire September 7, 2018

Exelixis to Present at the Morgan Stanley Global Health Care Conference on September 12, 2018

Business Wire September 5, 2018

Recent Analysis Shows KB Home, Sleep Number, Exelixis, Sprint, PayPal, and Halozyme Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth

GlobeNewswire August 23, 2018

Exelixis Announces Second Quarter 2018 Financial Results and Provides Corporate Update

Business Wire August 1, 2018

Free Technical Research Reports on Biotech Stocks -- Epizyme, Esperion Therapeutics, Exelixis, and Grifols

PR Newswire July 27, 2018

Exelixis to Release Second Quarter 2018 Financial Results on Wednesday, August 1, 2018

Business Wire July 17, 2018

Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published in The New England Journal of Medicine

Business Wire July 4, 2018

Exelixis to Be Added to the S&P MidCap 400 Index

Business Wire June 27, 2018